Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Sarcoma 1Primary Myelofibrosis 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mesothelioma, Malignant 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia 1Leiomyosarcoma 1Glioblastoma 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinosarcoma 1Adenocarcinoma of Lung 1

Interventions

ruxolitinib 2Azacitidine 2rucaparib 1avelumab 1abiraterone 1Watchful Waiting 1Tretinoin 1Pemetrexed 1Paclitaxel 1Nivolumab 1Imatinib Mesylate 1INCB059872 1INCB057643 1Gemcitabine 1Fentanyl 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Primary Myelofibrosis × rucaparib × Thoracic × Clear all
NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
137 enrolled 31 charts
BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡